Drugs / BC-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05162326 | Dec 2026 → Dec 2027 expected | — | Bright Cell, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05162326 ↗ |
| Modality | Cell therapy | “Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension” NCT05162326 ↗ |
| Route | Subcutaneous | “administered via subcutaneous/intradermal injection” NCT05162326 ↗ |